Molecular Devices Introduces EarlyTox Cell Viability Assay Kits

Share Article

Molecular Devices® today announced the launch of six EarlyTox™ cell viability assay kits, a new family of fluorescence-based reagents optimized for microplate readers to assess cell viability, cell proliferation, and apoptosis events in mammalian cells.

Cell viability assays are critical to a broad spectrum of research areas ranging from understanding the mechanisms of cell death to the development of apoptosis-related therapeutics. The EarlyTox cell viability assay kits have been optimized for highly sensitive and accurate microplate-based detection which provide a complete solution for evaluating cell viability.

Tailored for every research need, these assay kits employ a no-wash, homogeneous assay protocol with a simple workflow that reduces the variability typically introduced with multiple experimental steps. The use of a proprietary Masking Reagent reduces the fluorescence background for enhanced signal/background ratio. The assay kits have been validated for use on the Molecular Devices SpectraMax® family of microplate readers and other commercially available microplate readers for optimal performance. Every step, from instrument setup through data analysis, is simple using SoftMax® Pro Software from Molecular Devices, the industry-leading microplate reader control and analysis software. Each assay kit has a preconfigured protocol in SoftMax Pro Software that is ready to use.

Brian Quast, Senior Director of Marketing at Molecular Devices, commented: “The addition of the EarlyTox cell viability family of products provides a complete solution for cell viability experimentation that includes reagents, microplate instruments, and software analysis to simplify complex workflows to deliver high-performance results.”

For more information, please visit

About Molecular Devices, LLC

Molecular Devices is one of the world's leading providers of high-performance bioanalytical measurement systems, software and consumables for life science research, pharmaceutical and biotherapeutic development. Included within a broad product portfolio are platforms for high-throughput screening, genomic and cellular analysis, colony selection and microplate detection. These leading-edge products enable scientists to improve productivity and effectiveness, ultimately accelerating research and the discovery of new therapeutics. Molecular Devices is committed to the continual development of innovative solutions for life science applications. The company is headquartered in Silicon Valley, California with offices around the globe.

For more information about the complete product portfolio, visit

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Robert McInroy
Visit website